Type 2 & other diabetes

The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial

Diabetes Obes MetabPublished Pooled individual participant data subgroup analysis of the CANVAS Program and CREDENCE randomised trials

Authors' conclusion

The cardiovascular and renal benefits of canagliflozin and its safety profile were consistent across population-specific BMI subgroups for adults in the CANVAS Program and CREDENCE trial.

Study context

Population
Adults with T2D in the CANVAS Program and CREDENCE trial; 9378 (65%) with obesity
Participants
14,520 adults
Comparison
Canagliflozin vs comparator across population-specific body mass index (BMI) categories
Primary endpoint
MACE (nonfatal MI, nonfatal stroke or cardiovascular death); composite renal outcome; changes in SBP, body weight, albuminuria and eGFR slope
Methodological detailssubgroups by population-specific BMI
  • Subgroups by population-specific BMI

Primary result

As reported in the abstract

Treatment effect across BMI subgroups
Major adverse cardiovascular events (MACE): no heterogeneity across BMI subgroups
Pheterogeneity = 0.76
Composite renal outcome: no heterogeneity across subgroups
Pheterogeneity = 0.72
Body weight: effect differed across BMI subgroups
Pheterogeneity <0.01
Systolic blood pressure (SBP): effect differed across BMI subgroups
0.04
Albuminuria: effect consistent across subgroups
Pheterogeneity = 0.60
Chronic estimated glomerular filtration rate (eGFR) slope: consistent across subgroups
Pheterogeneity >0.95

Further findings

MACE, overall

HR (95% CI)
Canagliflozin0.83 (0.75–0.93)

Composite renal outcome, overall

HR (95% CI)
Canagliflozin0.75 (0.66–0.84)

Original publication

The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. Published 6 September 2023. doi:10.1111/dom.15267

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.